ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Pharmaceuticals

Inimmune raises $22 million for innate immune system drug discovery

by Ryan Cross
July 18, 2020 | APPEARED IN VOLUME 98, ISSUE 28

 

Inimmune, a Montana-based start-up, has raised $22 million in series A funding to develop compounds that stimulate the innate immune system. Founded in 2016 by chemists, formulation scientists, and immunologists who had worked in GlaxoSmithKline’s vaccines business, Inimmune has developed compounds that activate Toll-like receptors. The company plans preclinical studies to test the compounds as treatments for allergies, cancer, and viral infections—including the novel coronavirus.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment